WallStreetZenWallStreetZen

NASDAQ: HALO
Halozyme Therapeutics Inc Stock Ownership - Who owns Halozyme Therapeutics?

Insider buying vs selling

Have Halozyme Therapeutics Inc insiders been buying or selling?
Buy
Sell
NameRoleDateSharesPriceValue
Michael J. LabarreSVP CHIEF TECHNICAL OFFICER2024-04-1710,000$38.49
$384.89kSell
Michael J. LabarreSVP CHIEF TECHNICAL OFFICER2024-04-1710,000$8.11
$81.10kBuy
Michael J. LabarreSVP CHIEF TECHNICAL OFFICER2024-04-1610,000$8.11
$81.10kBuy
Michael J. LabarreSVP CHIEF TECHNICAL OFFICER2024-04-1610,000$38.35
$383.50kSell
Michael J. LabarreSVP CHIEF TECHNICAL OFFICER2024-03-262,890$8.11
$23.44kBuy
Michael J. LabarreSVP CHIEF TECHNICAL OFFICER2024-03-26292$16.78
$4.90kBuy
Michael J. LabarreSVP CHIEF TECHNICAL OFFICER2024-03-268,436$12.07
$101.82kBuy
Michael J. LabarreSVP CHIEF TECHNICAL OFFICER2024-03-1310,000$42.27
$422.73kSell
Michael J. LabarreSVP CHIEF TECHNICAL OFFICER2024-03-133,551$8.11
$28.80kBuy
Michael J. LabarreSVP CHIEF TECHNICAL OFFICER2024-03-136,449$12.07
$77.84kBuy

1 of 9

HALO insiders have sold more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when HALO insiders and whales buy or sell their stock.

HALO Shareholders

What type of owners hold Halozyme Therapeutics Inc stock?
Institutional
Insider
Retail
NameHoldSharesValueType
Randal J. Kirk21.00%26,633,924$1.01BInsider
Blackrock Inc14.69%18,630,963$704.44MInstitution
Vanguard Group Inc10.45%13,259,514$501.34MInstitution
Artisan Partners Limited Partnership5.27%6,689,058$252.91MInstitution
State Street Corp5.11%6,475,549$244.84MInstitution
Snyder Capital Management L P2.92%3,709,599$140.26MInstitution
Gregory Ian Frost2.87%3,641,380$137.68MInsider
Alliancebernstein LP2.73%3,463,694$130.96MInstitution
Macquarie Group Ltd2.59%3,282,640$124.12MInstitution
Jpmorgan Chase Co2.44%3,093,932$116.98MInstitution

1 of 3

HALO vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
HALO78.23%21.77%Net SellingNet Selling
KRYS75.55%24.45%Net SellingNet Selling
BPMC81.64%18.36%Net SellingNet Selling
CRSP62.44%37.56%Net BuyingNet Buying
BBIO55.86%44.14%Net SellingNet Selling

Halozyme Therapeutics Stock Ownership FAQ

Who owns Halozyme Therapeutics?

Halozyme Therapeutics (NASDAQ: HALO) is owned by 97.89% institutional shareholders, 27.24% Halozyme Therapeutics insiders, and 0.00% retail investors. Randal J. Kirk is the largest individual Halozyme Therapeutics shareholder, owning 26.63M shares representing 21.00% of the company. Randal J. Kirk's Halozyme Therapeutics shares are currently valued at $1.03B.

If you're new to stock investing, here's how to buy Halozyme Therapeutics stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.